Offices of Biotechnology and Business Development

Guiding Principles for Global Access and Technology Transfer '

Albert Einstein College of Medicine is committed to “innovative biomedical investigation and to the development of ethical and compassionate physicians and scientists.”  The Office of Biotechnology serves as the technology transfer office of Einstein, facilitating the licensing of College technology to industry and research collaborations between industry and faculty. The Office of Business Development serves to further enhance the value of the College's research, clinical and intellectual property assets by proactively collaborating with the commercial, governmental, financial and entrepreneurial communities in novel initiatives. Together, the Offices work in partnership and build upon each other’s strengths, in order to fulfill the mission of assisting the translation of basic research advances made at Einstein into clinical applications that can benefit the public. The Offices recognize the problem of affordable access to medical technologies in developing countries (i.e., The World Bank’s listing of low- and lower-middle-income economies), and the Offices realize that living up to their mission of serving the public includes doing their part to make Einstein-developed innovations accessible to people in the developing world whose lives depend on their use. This work is part of a broader institutional effort to address the challenges of global health through a multi-disciplinary approach, from the development of knowledge and technologies to the delivery of treatment and care. 

Einstein recognizes that global access to medicines and health-related technologies is important in fulfilling its mission of assisting the translation of basic research advances made at Einstein into clinical applications that can benefit the public. Einstein also recognizes its licensing strategy in relevant cases should be sufficiently transparent to verify its effectiveness.   

Toward these goals, Einstein has adopted the following guiding principles into its licensing program: 

  

1. Einstein reaffirms its commitment to seek out global licensing partners, corporate or otherwise, for new and neglected technologies that may be of significant interest to the developing world. 

Einstein has a history of licensing technology to partners that develop drugs, diagnostics, and vaccines to address diseases affecting the developing world.  Einstein reaffirms its commitment to these efforts by seeking out partners and using approaches that work to increase access in the developing world to therapies developed by Einstein scientists. 

Einstein recognizes that some corporate partners may not immediately recognize the value in global access strategies, and Einstein is committed to being a vigorous advocate for licensing technology in ways that promote global access. Einstein realizes that historically there has been a lack of incentives for companies to invest in neglected diseases, and therefore is committed to also seeking out non-corporate partners with the goal of facilitating access to Einstein-developed technologies.   

  

2. Einstein will engage in open and honest discussions with its industry partners to develop creative and effective licensing strategies that promote global access, including strategies that promote affordable access in developing countries.  

As market conditions evolve (e.g., the Doha Declaration on the TRIPS Agreement and Public Health), licensing with global access clauses are likely to become less threatening to licensees. Governmental and philanthropic resource availability, socially conscious investors and activists, compulsory licensing, and improved technology to prevent re-importation are just a few of the developments that are changing licensee perspectives. 

Through open discussion and creative thinking, Einstein and its licensing partners can develop licensing terms with which both parties are comfortable in order to promote global access. 

             

3. Einstein supports making new products available in the developing world and therefore will negotiate with licensing partners in a manner that promotes affordable access in these regions. 

Einstein encourages the development and dissemination of new products to address diseases specific to the developing world. Einstein recognizes that traditional licensing methods are not always sufficient for global access. Therefore, Einstein will negotiate with its partners for new, innovative licensing provisions that allow for global access.  

Einstein values the importance of access, as well as the value of financial return in order to incentivize innovation to develop new products. Recognizing that aspirational statements are not sufficient, Einstein is committed to seeking results.  

  

4. Einstein will continue to follow effective global access principles when licensing Einstein inventions, and is committed to developing new, innovative licensing strategies to promote access.  

The nature of licensing and the rapidly increasing attention to global access would render any list of socially responsible licensing strategies incomplete.  Einstein is therefore committed to thinking flexibly and creatively about bringing the stakeholders together in a mutually rewarding dynamic. 

' Adapted from Emory University Office of Technology Transfer

Click here to log in